Fig. 1
From: PRKCSH contributes to tumorigenesis by selective boosting of IRE1 signaling pathway
The level of PRKCSH is increased in various cancer tissues. a Map of human organs in which the expression of PRKCSH mRNA is significantly higher in tumors than in nontumor. Gene-expression datasets from TCGA were analyzed by using the GEPIA web tool. b Scatter plots showing relative levels of PRKCSH mRNA in nontumor and tumor tissues. Median expression levels in each group are indicated by horizontal lines and these values are shown in (a). One-way ANOVA; *P < 0.01. c Representative immunohistochemical images, and d relative levels of PRKCSH protein. The intensity of PRKCSH staining in paraffin-embedded sections of liver tissue arrays (nontumor, n = 59; tumor, n = 58) was calculated as described in Supplementary Fig. 1c. Scale bars represent 20 µm. The center line of the boxplots denotes the median, the bounds of the box indicate 25–75% and the whiskers represent 5–95%, respectively. Significance of the differences between the two categories was determined by the Student t test (P < 0.0001). e Immunoblot analysis of PRKCSH expression in human liver cell lines. f Relationship between PRKCSH expression and clinicopathological features. Among the clinicopathological data of the liver tissue array, extrahepatic metastasis and TNM stage were positively related to PRKCSH staining (Supplementary Table 1). g Overall survival and disease-free survival curves for patient groups with high and low PRKCSH expression level. The data were obtained from TCGA datasets. Significance of the differences between the two categories was determined by Log-rank test
